Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

BillionToOne (BLLN): which funds own it

Health Care →(by SIC code, unreviewed)Data as of Jun 30, 2026 (Q2 2026) · updated on Nov 5, 2026

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Follow BLLN for free
Share

Sections with a free account

3 concentrated managers hold it (+2 vs last quarter) with a median weight of 0.1%.

Who owns BillionToOne?

Holders that filed a Schedule 13D or 13G with the SEC for owning more than 5% of the Class A shares: Hummingbird Ventures Management (13D filed Jan 20, 2026), Krishna Kittu Kolluri ("Kolluri") (13G filed Feb 13, 2026), Oguzhan Atay (13G filed Feb 17, 2026) and David Tsao (13G filed Feb 17, 2026). As of Jun 30, 2026, the largest holders of Class A reported on Form 13F were Adams Street Partners (4.1% of Class A), Price T Rowe Associates (2.4%) and Baillie Gifford (2.2%).

Which institutions hold the most BillionToOne shares?

Per Form 13F filings as of Jun 30, 2026, as a share of Class A:

  1. 1. Adams Street Partners: 4.1%
  2. 2. Price T Rowe Associates: 2.4%
  3. 3. Baillie Gifford: 2.2%
  4. 4. Vanguard Portfolio Management: 2.0%
  5. 5. Invesco: 2.0%
  6. 6. Vanguard Capital Management: 1.9%
  7. 7. Neuberger Berman Group: 1.8%
  8. 8. Bamco: 1.8%
  9. 9. Wasatch Advisors: 1.3%
  10. 10. Millennium Management: 1.0%

How much of BillionToOne do institutions own?

The 155 institutions that file 13F reported 36.9% of the Class A shares as of Jun 30, 2026.

Sources:13D by Hummingbird Ventures Management (Jan 20, 2026) ↗13G by Krishna Kittu Kolluri ("Kolluri") (Feb 13, 2026) ↗13G by Oguzhan Atay (Feb 17, 2026) ↗13G by David Tsao (Feb 17, 2026) ↗All of the company's proxy statements on EDGAR ↗

13F percentages divide the shares each institution reports by the Class A shares outstanding on the cover of the company's latest report before the quarter end (May 4, 2026). Entities of the same group file separately and are not added up. With more than one share class, a 13D or 13G counts shares convertible from another class as owned, so we do not show its percentage. We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

BillionToOne revenue

BillionToOne reported annual revenue of $305.1 million for fiscal year 2025 (year ended December 31, 2025), according to its Form 10-K filed with the SEC (XBRL data).

Concentrated managers
3
All 13F: 155
Consensus
—
No score: it needs 5 or more concentrated managers
Price at Jun 30, 2026 (per 13F)
$119.98
+52.0% in the quarter · reported value ÷ shares, not the quote · See current quote ↗

Quarter flow (concentrated managers)

Change in managers (1 → 3): 2 opened · 0 exited = +2

Net flow in the quarter: +$854K (+7 K shares) · bought $854K and sold $0Shares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.

Concentrated managers holding it

Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.

Other relevant holders

Filers with $100M or more in the stock that do not count as concentrated managers because of their type: they are left out of the counts, the consensus and the accumulation.

  • Adams Street PartnersPrivate equity or venture capital$205M46.4%

Largest holders of BLLN (all 13F filers)

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Fundamentals

12-month figures to Sep 30, 2026 · balance sheet as of Sep 30, 2026.

Profitability
Operating margin
10.2%
Net margin
11.3%
ROE
8.7%
Growth
Revenue (TTM)
$437M
Revenue growth
71.9%
Net income (TTM)
$49.4M
Balance sheet
Net debt / EBITDA
−9.1x
Free cash flow (TTM)
$33.9M
Quality vs sector
—

This company's sector comes from its SIC code, unreviewed, or has too few comparable companies: we do not compare it with its sector.

Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated

Earnings quality and debt

Operating cash flow ÷ net income (12 months)
0.97
Interest coverage (operating income ÷ interest)
169 timesfiscal 2025
Debt due within 12 months
$385K0.00 times cash and investments
Debt maturities by year (note as of Sep 30, 2026)
  • Year 1—
  • Year 2—
  • Year 3—
  • Year 4—
  • Year 5—
  • Later$80.0M

From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.

Insiders (Form 4)

Officers and directors who bought (6 m)
0
Amount (6 m)
$0
CEO/CFO bought (12 m)
No

10% owners who bought (6 m): 0

Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.

Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →

Above 5% (13D/13G)

Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.

This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.

  • David Tsao6.9%13Gfiling ↗Event: Dec 31, 2025 · filed: Feb 17, 2026
  • Oguzhan Atay7.3%13Gfiling ↗Event: Dec 31, 2025 · filed: Feb 17, 2026
  • Krishna Kittu Kolluri ("Kolluri")10.6%13Gfiling ↗Event: Nov 7, 2025 · filed: Feb 13, 2026

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

Flagged material events (8-K)

  • Mar 4, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

    «BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance»

  • Dec 9, 2025Routinefiling ↗

    Change in directors or officers (Item 5.02)

    «BillionToOne Reports Third Quarter 2025 Results»

Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.

All material events (8-K)

Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.

Other Health Care stocks in managers' portfolios

Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.

All of Health Care →

Follow BLLN for free

If someone reports a 5%+ stake, we email you (if you turn it on). And when you come back, see whether concentrated managers got in or out. No credit card.

Follow BLLN